The effectiveness of immunotherapy in NSCLC patients seems to depend not only on the presence of mutations in the KRAS gene, but primarily on the coexistence of other mutations, including mutations in the STK11, KEAP1, and TP53 genes. This evidence concerns the gene KRAS and non-small cell lung carcinoma.